Literature DB >> 7695406

Characteristics of nine newly derived mesothelioma cell lines.

H I Pass1, E J Stevens, H Oie, M G Tsokos, A D Abati, P A Fetsch, D J Mew, H W Pogrebniak, W J Matthews.   

Abstract

This report characterizes nine new cell lines derived from patients with malignant pleural mesothelioma. The lines were initiated between July 1990 and July 1992 from solid tumors (5 lines) or effusions (4 lines) and had proliferated for a period of at least 2 months without senescence. They were characterized by cell size, doubling time, immunohistochemical analyses, electron microscopy, and chromosomal karyotyping. Growth factor/cytokine elaboration was determined using enzyme-linked immunoassays. The established lines were similar in morphology to their parent tumor (ie, epithelial or sarcomatoid). Cell sizes ranged from 59 to 81 microns, and the doubling times varied from 31 to 65 hours. The lines stained with cytokeratin and showed expected negative staining for adenomarkers including B72.3 and carcinoembryonic antigen. All cell lines exhibited aneuploidy, with modal chromosome numbers between 40 and 81 and had multiple chromosomal aberrations. Significant production of granulocyte-monocyte colony-stimulating factor, leukemia inhibitory factor, platelet-derived growth factor, and interleukin-6 was seen. These new cell lines derived from human mesotheliomas can now be used to aid in the design of innovative treatment strategies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7695406     DOI: 10.1016/0003-4975(95)00045-m

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  59 in total

1.  Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis.

Authors:  Marie-Marthe Philippeaux; Jean-Claude Pache; Sophie Dahoun; Marc Barnet; John-Henri Robert; Jacques Mauël; Anastase Spiliopoulos
Journal:  Histochem Cell Biol       Date:  2004-09-15       Impact factor: 4.304

2.  A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas.

Authors:  Sherrill L Macura; Jedd M Hillegass; Jeremy L Steinbacher; Maximilian B MacPherson; Arti Shukla; Stacie L Beuschel; Timothy N Perkins; Kelly J Butnor; Melissa J Lathrop; Mutlay Sayan; Khan Hekmatyar; Douglas J Taatjes; Risto A Kauppinen; Christopher C Landry; Brooke T Mossman
Journal:  J Histochem Cytochem       Date:  2012-06-21       Impact factor: 2.479

3.  MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.

Authors:  Anand Singh; Nisan Bhattacharyya; Abhishek Srivastava; Nathanael Pruett; R Taylor Ripley; David S Schrump; Chuong D Hoang
Journal:  Mol Ther       Date:  2019-06-04       Impact factor: 11.454

4.  Preclinical development of HIvax: Human survivin highly immunogenic vaccines.

Authors:  Peter R Hoffmann; Maddalena Panigada; Elisa Soprana; Frances Terry; Ivo Sah Bandar; Andrea Napolitano; Aaron H Rose; Fukun W Hoffmann; Lishomwa C Ndhlovu; Mahdi Belcaid; Lenny Moise; Anne S De Groot; Michele Carbone; Giovanni Gaudino; Takashi Matsui; Antonio Siccardi; Pietro Bertino
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter.

Authors:  Christina Cherian; Sita Kugel Desmoulin; Lei Wang; Lisa Polin; Kathryn White; Juiwanna Kushner; Mark Stout; Zhanjun Hou; Aleem Gangjee; Larry H Matherly
Journal:  Cancer Chemother Pharmacol       Date:  2013-02-15       Impact factor: 3.333

6.  Curcumin: a double hit on malignant mesothelioma.

Authors:  Jill M Miller; Joyce K Thompson; Maximilian B MacPherson; Stacie L Beuschel; Catherine M Westbom; Mutlay Sayan; Arti Shukla
Journal:  Cancer Prev Res (Phila)       Date:  2014-01-15

7.  In vitro and in vivo characterization of highly purified human mesothelioma derived cells.

Authors:  Alice Melotti; Antonio Daga; Daniela Marubbi; Annalisa Zunino; Luciano Mutti; Giorgio Corte
Journal:  BMC Cancer       Date:  2010-02-22       Impact factor: 4.430

8.  Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas.

Authors:  Arti Shukla; Jill M Miller; Christopher Cason; Mutlay Sayan; Maximilian B MacPherson; Stacie L Beuschel; Jedd Hillegass; Pamela M Vacek; Harvey I Pass; Brooke T Mossman
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

9.  Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects.

Authors:  Alla V Ivanova; Sergey V Ivanov; Ljudmila Prudkin; Daisuke Nonaka; Zhandong Liu; Anne Tsao; Ignacio Wistuba; Jack Roth; Harvey I Pass
Journal:  Mol Cancer       Date:  2009-10-24       Impact factor: 27.401

10.  Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.

Authors:  B J Stish; S Oh; H Chen; A Z Dudek; R A Kratzke; D A Vallera
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 9.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.